Introduction
Hand, foot, and mouth disease (HFMD) is a ubiquitous viral illness, predominantly affecting infants and young children, though adult cases are also observed. Characterized by distinctive vesicular eruptions, HFMD typically manifests on the hands, feet, and oral mucosa. In some instances, lesions can extend to the buttocks and genital area. While coxsackievirus A type 16 is frequently identified as the causative agent, a spectrum of coxsackieviruses and enteroviruses can induce this infection. Coxsackieviruses belong to the Picornaviridae family, a group of non-enveloped, single-stranded RNA viruses. Accurate and timely Coxsackievirus Diagnosis is paramount for effective patient management, preventing disease spread, and alleviating parental anxiety. This article provides an in-depth review of HFMD, emphasizing the critical aspects of coxsackievirus diagnosis, clinical presentation, and current management strategies for healthcare professionals.
Etiology: Unpacking the Viral Culprits
HFMD is classified as a viral exanthem, with viruses from the Enterovirus genus being the primary etiological agents. Among these, Coxsackievirus A16 (CV-A16) and Enterovirus A71 (EV-A71) are the most frequently implicated serotypes in HFMD cases globally. However, the landscape of HFMD etiology is evolving. Coxsackievirus A6 (CV-A6) has emerged as a significant cause of HFMD outbreaks in the United States and worldwide, often associated with more atypical and severe presentations, especially in adults. Furthermore, Coxsackievirus A10 (CV-A10) has been linked to severe HFMD cases. It’s important to note that a range of other coxsackieviruses, including types A4, A5, A7, A9, B1, B2, B3, and B5, have also been less commonly associated with the disease, highlighting the diverse viral etiology of HFMD and the complexities it introduces for coxsackievirus diagnosis.
Epidemiology: Global Distribution and Trends
HFMD is not geographically restricted, occurring worldwide with varying prevalence patterns. Children under 7 years, especially those in daycare or summer camps, exhibit higher infection rates, leading to frequent outbreaks in these settings and within families. Surveillance data from China, a region with significant HFMD burden, indicates that over 90% of cases occur in children under 5 years old. These studies also reveal a seasonal trend, with increased incidence during late spring and early summer. Environmental factors also play a role; research in Vietnam demonstrated a positive correlation between elevated environmental temperature and humidity and increased HFMD incidence. Interestingly, recent surveillance in France (2021) reported a surge in HFMD cases, with Enterovirus being the predominant type, but atypical presentations were linked to Coxsackievirus A6 and A16. In the United States, Coxsackievirus A6 has become the dominant cause of HFMD, underscoring the shifting epidemiology and the need for vigilance in coxsackievirus diagnosis and surveillance.
Pathophysiology: How Coxsackievirus Spreads and Infects
The transmission of human enteroviruses, including coxsackieviruses, primarily occurs through the fecal-oral route and respiratory droplets. Ingestion of virus shed from infected individuals’ gastrointestinal or upper respiratory tracts, direct contact with vesicle fluid, or oral secretions are the main modes of spread. Patients are most contagious during the first week of illness, with an incubation period typically ranging from 3 to 6 days. Following ingestion, the virus replicates initially in the lymphoid tissue of the lower intestine and pharynx. From these primary sites, the virus disseminates to regional lymph nodes, potentially spreading hematogenously to various organs, including the central nervous system (CNS), heart, liver, and skin. Understanding this pathophysiology is crucial for implementing effective infection control measures and appreciating the systemic nature of enteroviral infections, even in seemingly localized diseases like HFMD. For accurate coxsackievirus diagnosis, recognizing the typical disease progression is also beneficial.
History and Physical Examination: Recognizing HFMD Clinically
The clinical presentation of HFMD often begins with prodromal symptoms like low-grade fever, reduced appetite, and general malaise. The hallmark symptom is typically mouth or throat pain, resulting from the enanthem. Oral lesions initially appear as vesicles surrounded by a thin halo of erythema. These vesicles rapidly rupture, forming superficial ulcers with a characteristic grey-yellow base and erythematous rim. The exanthem, the skin rash, can be macular, papular, or vesicular. These lesions, typically 2 to 6 mm in size, are usually non-pruritic and not intensely painful. They generally persist for about 10 days, eventually rupturing and evolving into painless, shallow ulcers that heal without scarring. The exanthem commonly involves the dorsum of the hands and feet, but can also appear on the buttocks, legs, and arms. Oral lesions are frequently found on the buccal mucosa and tongue but can also extend to the soft palate.
It is crucial to recognize that HFMD can present with atypical features. Neurological complications, such as aseptic meningitis, are a recognized concern. Enteroviruses, including those causing HFMD, are known for their neurotropism and can cause a range of CNS manifestations, including encephalitis, polio-like syndrome, acute transverse myelitis, Guillain-Barre syndrome, benign intracranial hypertension, and acute cerebellar ataxia. Therefore, a thorough physical examination and detailed history, including neurological assessment, are vital for comprehensive patient evaluation and guiding appropriate coxsackievirus diagnosis and management strategies.
Clinical Presentation of Hand, Foot, and Mouth Disease: Image depicting the characteristic rash and oral lesions associated with HFMD, emphasizing key visual diagnostic features for healthcare professionals.
Evaluation and Coxsackievirus Diagnosis: Confirming the Etiology
While HFMD diagnosis is often clinically based on the characteristic history and physical findings, laboratory confirmation can be crucial, particularly in atypical presentations, during outbreaks, or for epidemiological surveillance. Viral shedding in stool can persist for up to 6 weeks post-infection, while oropharyngeal shedding typically lasts less than 4 weeks. Light microscopy of vesicle scrapings or biopsies can help differentiate HFMD from other vesicular exanthems like varicella-zoster virus and herpes simplex virus infections. However, these methods are not specific for coxsackievirus diagnosis.
Serology has limited utility in acute coxsackievirus diagnosis due to its low sensitivity. While IgG levels can be measured to monitor recovery or for seroprevalence studies, acute diagnostic decisions rarely rely on serology. In specialized centers, serology might be used to differentiate enterovirus 71 from coxsackieviruses, as this distinction can have prognostic implications, especially in regions where EV-A71 associated severe disease is prevalent.
The gold standard for definitive coxsackievirus diagnosis is polymerase chain reaction (PCR) assays. Real-time PCR assays are readily available in most diagnostic centers and can detect coxsackievirus or enterovirus RNA in lesion swabs, throat swabs, or stool samples. PCR offers rapid and sensitive detection, enabling specific viral identification and aiding in epidemiological tracking of circulating strains. In cases of suspected neurological involvement, cerebrospinal fluid (CSF) analysis with viral PCR may be warranted to confirm enteroviral neuroinvasion. Therefore, while clinical acumen remains paramount, laboratory tools, especially PCR, play an increasingly important role in accurate and timely coxsackievirus diagnosis, informing clinical management and public health strategies.
Treatment and Management: Supportive Care and Emerging Therapies
HFMD is typically a mild, self-limiting illness, resolving spontaneously within 7 to 10 days. Consequently, treatment is primarily supportive, focused on symptom relief and preventing complications. Pain and fever, common complaints, can be effectively managed with over-the-counter analgesics and antipyretics such as nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and acetaminophen (paracetamol). Maintaining adequate hydration is crucial, especially in young children who may experience reduced oral intake due to painful mouth ulcers. In some cases, topical oral rinses or gargles containing a mixture of ibuprofen and diphenhydramine can provide local pain relief by coating the oral ulcers.
It’s important to note that steroid use is contraindicated in HFMD as studies have suggested it may increase the risk of severe disease. While specific antiviral therapies for coxsackievirus-induced HFMD are not currently licensed for routine clinical use, research is ongoing, particularly for severe enterovirus 71 infections. Promising novel agents under investigation include molecular decoys, translation inhibitors, receptor antagonists, and replication inhibitors. Pleconaril, an anti-picornaviral agent, has shown some promise against enterovirus 71 in research settings, but is not yet a standard treatment. Anecdotal reports have suggested potential benefit from acyclovir, but large-scale clinical trials have not confirmed its efficacy in HFMD.
Vaccine development for HFMD is an active area of research. Inactivated, whole-virus, aluminum-adjuvant vaccines against EV-A71 have been developed and approved for widespread use in China, demonstrating high efficacy in preventing EV-A71 associated HFMD. Other vaccine candidates, including virus-like particles, DNA, peptide, and subunit vaccines, are in various stages of clinical trials. For now, supportive care remains the cornerstone of HFMD management, with ongoing research paving the way for potential targeted antiviral therapies and preventative vaccines, especially against severe strains like EV-A71. Accurate coxsackievirus diagnosis remains vital to differentiate HFMD from other conditions and guide appropriate supportive care.
Differential Diagnosis: Distinguishing HFMD from Mimicking Conditions
The differential diagnosis of HFMD encompasses a range of conditions that present with maculopapular or vesicular rashes, with or without oral lesions. Accurate coxsackievirus diagnosis requires careful differentiation from these mimicking illnesses. Key differential diagnoses include:
- Herpangina: Caused by other coxsackieviruses, herpangina primarily involves painful vesicles and ulcers in the posterior oropharynx, without significant hand or foot involvement.
- Herpes simplex virus (HSV) infection: Oral herpes (gingivostomatitis) can present with painful oral vesicles and ulcers, but typically lacks the characteristic hand and foot rash of HFMD. Genital herpes can also be considered in the differential, especially if genital lesions are prominent in HFMD.
- Varicella-zoster virus infection (chickenpox): Chickenpox presents with a more generalized, pruritic vesicular rash in different stages of development, often including the trunk, and typically lacks the specific hand, foot, and mouth distribution of HFMD.
- Erythema multiforme: This hypersensitivity reaction can cause target-like lesions on the extremities and mucous membranes, potentially mimicking HFMD, but lacks the typical vesicular nature of HFMD lesions.
- Kawasaki disease: This systemic vasculitis, primarily in young children, can present with oral mucosal changes (strawberry tongue, lip cracking), rash, and hand/foot edema and erythema, but typically includes other distinct features like fever lasting >5 days, conjunctivitis, and lymphadenopathy, which are not typical of HFMD.
- Steven-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN): These severe mucocutaneous reactions, often drug-induced, can present with widespread blistering and mucosal involvement, but are usually more severe and systemic than HFMD.
- Viral pharyngitis: While HFMD includes oral lesions, viral pharyngitis typically presents with sore throat, fever, and other respiratory symptoms, without the characteristic hand and foot rash.
- Rocky Mountain spotted fever: This tick-borne illness can cause a maculopapular rash, including on palms and soles, but is associated with fever, headache, and a history of tick exposure, and is geographically restricted to certain areas.
- Monkeypox: In the context of recent outbreaks, monkeypox should be considered, as it can present with vesicular rash and oral lesions, potentially mimicking HFMD, particularly in adults or atypical presentations. However, monkeypox lesions tend to be more synchronous in development and may have a different distribution.
A careful clinical evaluation, considering the patient’s age, symptoms, rash distribution, and epidemiological context, is crucial for accurate differential diagnosis and appropriate management. Laboratory confirmation, especially PCR for enteroviruses, can be helpful in ambiguous cases or during outbreaks to confirm coxsackievirus diagnosis and rule out other conditions.
Prognosis and Complications: Understanding Disease Course and Potential Risks
The prognosis for the vast majority of patients with HFMD is excellent. Most individuals recover fully within a few weeks (typically 10 to 14 days) without any long-term sequelae. Recurrent or persistent infection is rare. However, it’s important to be aware that HFMD, particularly when caused by certain enteroviruses like EV-A71, can be associated with serious complications, although these are uncommon.
Rare complications reported in association with HFMD include:
- Neurological complications: Aseptic meningitis, encephalitis, acute flaccid paralysis (polio-like syndrome), and cerebellar ataxia are the most concerning complications. EV-A71 is more frequently linked to severe neurological disease compared to CV-A16.
- Systemic complications: Pneumonia, myocarditis, pancreatitis, and pulmonary edema are very rare but potentially life-threatening complications reported in association with HFMD. Serositis involving other major organs has also been described.
Risk factors for severe HFMD and fatal outcomes, identified in meta-analyses, include lethargy, pulmonary edema/hemorrhage, seizures, dyspnea, and coma. The case fatality rate associated with EV-A71 infection, though relatively low, is higher than with other coxsackieviruses, emphasizing the importance of recognizing and monitoring for potential complications, especially in EV-A71 associated cases. While most HFMD cases are benign, vigilance for warning signs and prompt medical attention are crucial to manage potential complications effectively. Accurate coxsackievirus diagnosis and strain identification (where possible) can aid in risk stratification and clinical decision-making.
Deterrence and Patient Education: Preventing Transmission
Patient and parental education are paramount in controlling the spread of HFMD, both among children and between children and adults. Handwashing is a proven, highly effective strategy for preventing HFMD transmission. Community intervention studies have demonstrated that intensive education on hand hygiene significantly improves personal hygiene practices in parents and children, leading to a reduction in HFMD incidence. Therefore, reinforcing proper handwashing techniques, especially after diaper changes, using the toilet, and before meals, is crucial in patient education.
Parents should also be advised to keep children with HFMD home from daycare or school during the acute phase of illness to minimize transmission to others. Educating parents about the modes of transmission (fecal-oral, respiratory droplets, direct contact) helps them understand the importance of hygiene measures. Furthermore, advising parents to avoid close contact between infected children and immunosuppressed individuals is important, as immunocompromised individuals may be at higher risk for more severe illness if infected with coxsackieviruses or enteroviruses. Effective patient education, coupled with public health initiatives promoting hygiene, forms the cornerstone of HFMD prevention and outbreak control. While coxsackievirus diagnosis focuses on identifying existing cases, preventive education aims to reduce future incidence.
Pearls and Other Issues: Key Clinical Considerations
Most patients with coxsackievirus-induced HFMD can be managed as outpatients. However, certain clinical scenarios warrant closer monitoring and potential hospitalization. Patients exhibiting signs of central nervous system involvement, such as lethargy, irritability, seizures, or altered mental status, require prompt neurological evaluation and may need hospital admission for close observation and supportive care. Neuroimaging studies of the brain may be necessary in such cases to guide management and assess prognosis.
Infants are particularly vulnerable to dehydration, especially if they develop painful oral ulcers, which can significantly impair oral intake. Intravenous hydration may be necessary in infants with poor oral intake and signs of dehydration. Hospital admission is strongly recommended for any infant with HFMD who presents with signs of severe disease, lethargy, dehydration, or neurological symptoms.
Given that coxsackievirus shedding in stool can persist for several weeks after infection, patients and caregivers should be educated about maintaining good personal hygiene and meticulous handwashing practices even after symptoms have resolved, to prevent ongoing transmission. Early and accurate coxsackievirus diagnosis is crucial for appropriate clinical management, guiding patient education, and implementing effective infection control measures.
Enhancing Healthcare Team Outcomes: A Collaborative Approach
With HFMD cases remaining prevalent, clinicians must maintain a high index of suspicion and be adept at recognizing and diagnosing the condition. Given the potential for neurological complications, especially with certain enteroviruses, a neurological consultation may be necessary in selected cases. Optimal management of HFMD, particularly in complicated cases, benefits from an interprofessional team approach. This team ideally includes physicians (MDs, DOs, NPs, or PAs) from primary care (pediatrics, family medicine, internal medicine) and specialist disciplines (neurology, infectious disease), nursing staff, and pharmacists.
Clinicians play the central role in diagnosis, initiating appropriate therapy (primarily supportive), and determining the need for specialist referrals. Pharmacists contribute by optimizing medication management, performing medication reconciliation to avoid drug interactions, and providing expert information about analgesics and other symptomatic treatments. Nurses are essential in coordinating care, collaborating with other team members, assisting with patient examinations, providing patient and family education, and monitoring for complications. Effective communication and collaboration among all team members are paramount to ensure comprehensive patient care, leading to optimal outcomes and minimizing potential complications of HFMD. Accurate and timely coxsackievirus diagnosis is the starting point for effective interprofessional management and improved patient outcomes. For most patients, the prognosis is excellent, with full recovery within 7 to 21 days, emphasizing the importance of reassurance and supportive care.
Review Questions
(Note: Review questions are present in the original article but are not included in the rewritten version as per instructions to focus on content enhancement and SEO).
References
(Note: The original references are retained in the rewritten version to maintain academic integrity and provide source material for readers.)
1.Woodland DL. Hand, Foot, and Mouth Disease. Viral Immunol. 2019 May;32(4):159. [PubMed: 31038400]
2.Zhu L, Yin H, Sun H, Qian T, Zhu J, Qi G, Wang Y, Qi B. The clinical value of aquaporin-4 in children with hand, foot, and mouth disease and the effect of magnesium sulfate on its expression: a prospective randomized clinical trial. Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1343-1349. [PubMed: 31028503]
3.Wu CY, Lin FL. Hand-foot-and-mouth-disease-induced Koebner phenomenon in psoriasis. J Dtsch Dermatol Ges. 2019 May;17(5):549-551. [PubMed: 30994243]
4.Muzumdar S, Rothe MJ, Grant-Kels JM. The rash with maculopapules and fever in children. Clin Dermatol. 2019 Mar-Apr;37(2):119-128. [PubMed: 30981292]
5.Nelson BR, Edinur HA, Abdullah MT. Compendium of hand, foot and mouth disease data in Malaysia from years 2010-2017. Data Brief. 2019 Jun;24:103868. [PMC free article: PMC6441719] [PubMed: 30976640]
6.Tsai YH, Huang SW, Hsieh WS, Cheng CK, Chang CF, Wang YF, Wang JR. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate. J Virol. 2019 Jul 01;93(13) [PMC free article: PMC6580961] [PubMed: 30996087]
7.Kimmis BD, Downing C, Tyring S. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis. 2018 Nov;102(5):353-356. [PubMed: 30566537]
8.Bian L, Gao F, Mao Q, Sun S, Wu X, Liu S, Yang X, Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev Anti Infect Ther. 2019 Apr;17(4):233-242. [PubMed: 30793637]
9.Sarma N. Hand, foot, and mouth disease: current scenario and Indian perspective. Indian J Dermatol Venereol Leprol. 2013 Mar-Apr;79(2):165-75. [PubMed: 23442455]
10.Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):391-398. [PubMed: 29411190]
11.Nguyen HX, Chu C, Tran QD, Rutherford S, Phung D. Temporal relationships between climate variables and hand-foot-mouth disease: a multi-province study in the Mekong Delta Region, Vietnam. Int J Biometeorol. 2020 Mar;64(3):389-396. [PubMed: 31720856]
12.Mirand A, Cohen R, Bisseux M, Tomba S, Sellem FC, Gelbert N, Béchet S, Frandji B, Archimbaud C, Brebion A, Chabrolles H, Regagnon C, Levy C, Bailly JL, Henquell C. A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro Surveill. 2021 Oct;26(43) [PMC free article: PMC8555367] [PubMed: 34713796]
13.Saguil A, Kane SF, Lauters R, Mercado MG. Hand-Foot-and-Mouth Disease: Rapid Evidence Review. Am Fam Physician. 2019 Oct 01;100(7):408-414. [PubMed: 31573162]
14.Broccolo F, Drago F, Ciccarese G, Genoni A, Porro A, Parodi A, Chumakov K, Toniolo A. Possible long-term sequelae in hand, foot, and mouth disease caused by Coxsackievirus A6. J Am Acad Dermatol. 2019 Mar;80(3):804-806. [PubMed: 30661911]
15.Rasti M, Khanbabaei H, Teimoori A. An update on enterovirus 71 infection and interferon type I response. Rev Med Virol. 2019 Jan;29(1):e2016. [PMC free article: PMC7169063] [PubMed: 30378208]
16.Coates SJ, Davis MDP, Andersen LK. Temperature and humidity affect the incidence of hand, foot, and mouth disease: a systematic review of the literature – a report from the International Society of Dermatology Climate Change Committee. Int J Dermatol. 2019 Apr;58(4):388-399. [PubMed: 30187452]
17.He Y, Yang J, Zeng G, Shen T, Fontaine RE, Zhang L, Shi G, Wang Y, Li Q, Long J. Risk factors for critical disease and death from hand, foot and mouth disease. Pediatr Infect Dis J. 2014 Sep;33(9):966-70. [PubMed: 24577041]
18.Kim B, Moon S, Bae GR, Lee H, Pai H, Oh SH. Factors associated with severe neurologic complications in patients with either hand-foot-mouth disease or herpangina: A nationwide observational study in South Korea, 2009-2014. PLoS One. 2018;13(8):e0201726. [PMC free article: PMC6086402] [PubMed: 30096160]
19.Velástegui J, Cova L, Galarza Y, Fierro P, León Baryolo L, Bustillos A. [A case report of hand, foot, and mouth disease with necrotizing mucocutaneous lesions]. Medwave. 2019 Aug 14;19(7):e7683. [PubMed: 31442216]
20.Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, Zhu FC. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15(1):129-37. [PubMed: 26460695]
21.Nayak G, Bhuyan SK, Bhuyan R, Sahu A, Kar D, Kuanar A. Global emergence of Enterovirus 71: a systematic review. Beni Suef Univ J Basic Appl Sci. 2022;11(1):78. [PMC free article: PMC9188855] [PubMed: 35730010]
22.Lewis A, Josiowicz A, Hirmas Riade SM, Tous M, Palacios G, Cisterna DM. Introduction and Differential Diagnosis of Monkeypox in Argentina, 2022. Emerg Infect Dis. 2022 Oct;28(10):2123-2125. [PMC free article: PMC9514367] [PubMed: 35960545]
23.Gonzalez G, Carr MJ, Kobayashi M, Hanaoka N, Fujimoto T. Enterovirus-Associated Hand-Foot and Mouth Disease and Neurological Complications in Japan and the Rest of the World. Int J Mol Sci. 2019 Oct 20;20(20) [PMC free article: PMC6834195] [PubMed: 31635198]
24.Park B, Kwon H, Lee K, Kang M. Acute pancreatitis in hand, foot and mouth disease caused by Coxsackievirus A16: case report. Korean J Pediatr. 2017 Oct;60(10):333-336. [PMC free article: PMC5687981] [PubMed: 29158768]
25.Ogilvie MM, Tearne CF. Spontaneous abortion after hand-foot-and-mouth disease caused by Coxsackie virus A16. Br Med J. 1980 Dec 06;281(6254):1527-8. [PMC free article: PMC1714960] [PubMed: 6254606]
26.Ni XF, Li X, Xu C, Xiong Q, Xie BY, Wang LH, Peng YH, Li XW. Risk factors for death from hand-foot-mouth disease: a meta-analysis. Epidemiol Infect. 2020 Feb 27;148:e44. [PMC free article: PMC7058831] [PubMed: 32102711]
27.Zhao YY, Jin H, Zhang XF, Wang B. Case-fatality of hand, foot and mouth disease associated with EV71: a systematic review and meta-analysis. Epidemiol Infect. 2015 Oct;143(14):3094-102. [PMC free article: PMC9151022] [PubMed: 25721492]
28.Zhang D, Li Z, Zhang W, Guo P, Ma Z, Chen Q, Du S, Peng J, Deng Y, Hao Y. Hand-Washing: The Main Strategy for Avoiding Hand, Foot and Mouth Disease. Int J Environ Res Public Health. 2016 Jun 18;13(6) [PMC free article: PMC4924067] [PubMed: 27322307]
29.Guo N, Ma H, Deng J, Ma Y, Huang L, Guo R, Zhang L. Effect of hand washing and personal hygiene on hand food mouth disease: A community intervention study. Medicine (Baltimore). 2018 Dec;97(51):e13144. [PMC free article: PMC6320109] [PubMed: 30572426]
Disclosures
Disclosure: Amanda Guerra declares no relevant financial relationships with ineligible companies.
Disclosure: Emily Orille declares no relevant financial relationships with ineligible companies.
Disclosure: Muhammad Waseem declares no relevant financial relationships with ineligible companies.
